Natera, Inc.
NTRA
#513
Rank
$48.786 B
Marketcap
United States
Country
$338.45
Share price
8.23%
Change (1 day)
102.26%
Change (1 year)
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic…
Key Metrics
Trailing P/E
—
Forward P/E
-3504.86
EPS (TTM)
$-1.36
Forward EPS
$-0.10
Price / Book
28.44
EV / EBITDA
-231.5x
Beta
1.53
Dividend Yield
—
Return on Equity
-12.54%
Return on Assets
-8.08%
Debt / Equity
13.09
Current Ratio
3.00
Gross Margin
65.23%
Operating Margin
-10.29%
Net Profit Margin
-7.11%
Free Cash Flow
$104.029M
Charts
Price history and financial performance over time.
Price & Market Cap
Aug 19 – Sep 18
+10.96%
Source: Yahoo Finance daily closes. Market cap uses the closest quarterly shares-outstanding filing for each date.
Revenue & Net Income
Annual · USD
RevenueNet Income
Latest Revenue$2.306B
Latest Net Income$-208,160,000
Reporting periods4
Source: Yahoo Finance annual income statements. Year is the fiscal-year end. Most recent period may be trailing-twelve-month (TTM) until the next 10-K is filed.
Compare Natera, Inc. with competitors
Side-by-side market cap, revenue, and financial comparison.
Latest News
Latest News
NTRA
No recent news available. Set FINNHUB_API_KEY to enable news.
